September 2017

Adjuvant therapy with TKIs for patients with high-risk renal cell carcinoma who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines, yet this approach is still controversial, with many physicians believing that there are not yet enough data in support of its use. 

Michael J. Birrer, MD, PhD, discusses the introduction of poly ADP-ribose polymerase inhibitors to the ovarian cancer treatment landscape.

Lori J. Wirth, MD, discusses the era of precision genotype targeted therapy in advanced thyroid cancer, with a focus on individual targets in subtypes of thyroid cancer.